AKR1B10 and metabolic dysfunction-associated steatohepatitis: Normal ranges of plasma/serum AKR1B10 have been different between studies, including the present study and cutoff levels of AKR1B10 for the prediction of NASH and/or advanced fibrosis and HCC varied and overlapped between different studies [14,16].